Dear Fellow Shareholders of Nutra Pharma: As we are getting close to the end of the year, I wanted to take this opportunity to update you on the current status of the Company, provide a review of 2016 and briefly outline our goals and expectations for the coming months. Nutra Pharma Corporation operates as a biotechnology and biopharmaceutical company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the manageme

December 27, 2016 Nutra Pharma CEO, Rik J Deitsch, has published a letter to Shareholders outlining the current efforts and the future goals of the Company. December 27, 2016 -- Coral Springs, Florida -- Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneur